Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

作者：Lv Meng; Huang Xiao Jun^*

来源：Journal of Hematology & Oncology, 2012, 5(1): 10.

DOI：10.1186/1756-8722-5-10

• China
• Allo-HSCT
• Haploidentical
• Relapse
• GVHD
• Elderly patients

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.

• 出版日期2012-3-18
• 单位北京大学